Search | IOVS | ARVO Journals

Showing 1 – 20 of 60

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

A 96-week PULSAR subgroup analysis: Similar visual and anatomic improvements with aflibercept 8 mg every 12 weeks or longer and 2 mg every 8 weeks, as defined by baseline BCVA, CRT, CNV type, and race

Richard Gale; Oliver Zeitz; Sobha Sivaprasad; Sergio Leal; Tobias Machewitz; xin Zhang

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4906.

ARVO Annual Meeting Abstract June 2024

From the Human Blood Metabolome to an Interventional Murine CNV Model: Unveiling Saccharin's Protective Effect on Neovascular AMD

Steffen Emil Künzel; Inga-Marie Pompös; Leonie T.M. Flesch; Dominik P. Frentzel; Vitus A. Knecht; Sergej Skosyrski; Anne Rübsam; Felix Dreher; Norbert Kociok; Alexandre Dubrac; Bodo Lange; Marie-Laure Yaspo; Hans Lehrach; Olaf Strauss; Antonia M. Joussen; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):213.

ARVO Annual Meeting Abstract June 2024

Choroidal Vessel Analysis in Central Serous Chorioretinopathy: Real-World Data from the Berlin Macula Registry

Payam Kabiri; Steffen Emil Künzel; Vitus A. Knecht; Shirin Ashraf Vaghefi; Anne Rübsam; Antonia M. Joussen; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6639.

Biochemistry and Molecular Biology April 2024

Exploring the Impact of Saccharin on Neovascular Age-Related Macular Degeneration: A Comprehensive Study in Patients and Mice

PDF

Steffen E. Künzel; Inga-Marie Pompös; Leonie T. M. Flesch; Dominik P. Frentzel; Vitus A. Knecht; Silvia Winkler; Sergej Skosyrski; Anne Rübsam; Felix Dreher; Norbert Kociok; Moritz Schütte; Alexandre Dubrac; Bodo Lange; Marie-Laure Yaspo; Hans Lehrach; Olaf Strauß; Antonia M. Joussen; Oliver Zeitz
TAGS: choroidal neovascularization, mice, saccharin, exudative age-related macular degeneration, metabolites
Invest. Ophthalmol. Vis. Sci.. 2024; 65(4):5. https://doi.org/10.1167/iovs.65.4.5

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2022

Transcriptome analysis of the human choroid qualifies endothelial androgen responses as a disease driver for Central Serous Chorioretinopathy

Steffen Emil Künzel; Sandrine Helene Künzel; Dominik Pascal Frentzel; Dominika Pohlmann; Lynn Zur Bonsen; Oliver Zeitz; Antonia M. Joussen; Alexandre Dubrac

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):39.

ARVO Annual Meeting Abstract June 2022

Metabolic factors influence CNV activity in neovascular AMD – insights from the BIOMAC study

Leonie Flesch; Dominik Frentzel; Saskia Rau; Anne Rübsam; Steffen Emil Künzel; Susanne Wolf; Felix Dreher; Moritz Schütte; Bodo Lange; Marie-Laure Yaspo; Hans Lehrach; Antonia M. Joussen; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):291 – F0094.

ARVO Annual Meeting Abstract June 2022

Phase I/IIa study examining the safety and tolerability of single and multiple rising intravitreal doses of BI 836880 in patients with wAMD

Oliver Zeitz; Albert Edwards; Allen Hu; Brian Berger; Gudrun Simons; michael ehrlich; Daniel Peter; Sobha Sivaprasad

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3124.

ARVO Annual Meeting Abstract June 2022

Modulation of clinical neovascular AMD activity by systemic proteome – an analysis from the BIOMAC study

Vitus André Knecht; Dominik Frentzel; Saskia Rau; Anne Rübsam; Steffen Emil Künzel; Susanne Wolf; Felix Dreher; Moritz Schütte; Bodo Lange; Hans Lehrach; Marie-Laure Yaspo; Antonia M. Joussen; Zeitz Oliver

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):274 – F0319.

ARVO Annual Meeting Abstract September 2016

Systemic Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor (VEGF) Agents in Patients With Wet Age-Related Macular Degeneration

Peter K Kaiser; Laurent Kodjikian; Jean-Francois Korobelnik; Oliver Zeitz; Robert Vitti; Carola Metzig; Christiane Ahlers; Thomas dicioccio; Joachim Hoechel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3366.

ARVO Annual Meeting Abstract September 2016

A combined phase 2a/b study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops in treatment-naïve patients with neovascular age-related macular degeneration (nAMD)

Antonia M Joussen; Sebastian Wolf; Peter K Kaiser; David S Boyer; Thomas Schmelter; Rupert Sandbrink; Oliver Zeitz; Michael K Boettger; Brigitte Stemper

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract June 2015

Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema: Evaluating the Impact on Diabetic Retinopathy

Paul Mitchell; Mark C Gillies; Michael Larsen; Giovanni Staurenghi; Frank G Holz; Todd A Katz; Chengxing Lu; Christiane Ahlers; Carola Metzig; Oliver Zeitz; VIVID-DME and VISTA-DME study investigators

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3146.

ARVO Annual Meeting Abstract June 2015

Intravitreal aflibercept shows consistent outcomes in Asian and white patients with wet age-related macular degeneration: novel results from the SIGHT and VIEW studies

Xiaoxin Li; Youxin Chen; JunJun Zhang; Xun Xu; Gemmy Cheung; Helen Wu; Rae Yu; Husain Kazmi; Olaf Sowade; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1658.

ARVO Annual Meeting Abstract June 2015

Effect of Baseline Central Retinal Thickness (CRT) and Best Corrected Visual Acuity (BCVA) on Treatment Outcomes With Intravitreal Aflibercept Injection (IAI) or Macular Laser Photocoagulation in Diabetic Macular Edema (DME)

Yuichiro Ogura; Nicolas Feltgen; Jean-Francois Korobelnik; Edoardo Midena; Todd A Katz; Claudia Teukmantel; Carola Metzig; Oliver Zeitz; VIVID-DME and VISTA-DME study investigators

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1748.

Physiology and Pharmacology September 2014

Vascular Dysfunction in Ocular Blood Flow Regulation: Impact of Reactive Oxygen Species in an Experimental Setup

PDF

Lars Wagenfeld; Sonja Weiss; Maren Klemm; Gisbert Richard; Oliver Zeitz
TAGS: adenosine triphosphatases, endothelium, membrane potentials, pathophysiology, reactive oxygen species, regulation, vascular flow, dilatation, pathologic
Invest. Ophthalmol. Vis. Sci.. 2014; 55(9):5531-5536. https://doi.org/10.1167/iovs.14-14032

ARVO Annual Meeting Abstract April 2014

Efficacy and Safety of Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Pathological Myopia: 48-week Results of MYRROR Study

Tien Y Wong; Tatsuro Ishibashi; Kyoko Ohno-Matsui; Yasushi Ikuno; Jean-Francois Korobelnik; Brigitte Stemper; Yoshimi Matsuda; Tummy Li; Robert Vitti; Oliver Zeitz; MYRROR

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4960.

ARVO Annual Meeting Abstract June 2013

Subanalysis of Visual Acuity Outcomes in the Second Year of VIEW Studies

Michaella Goldstein; Jean-Francois Korobelnik; Christiane Norenberg; Oliver Zeitz; VIEW investigators

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3171.

ARVO Annual Meeting Abstract June 2013

Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Yuichiro Ogura; Jean-Francois Korobelnik; Johann Roider; Robert Vitti; Frank Holz; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; GALILEO study investigators

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4516.

ARVO Annual Meeting Abstract March 2012

Microperimetry assessment of retinal sensitivity in patients with diabetic macular edema - results from the Phase 2 Da Vinci study

Victor H. Gonzalez; Diana V. Do; Husain Kazmi; Robert Vitti; Alyson J. Berliner; Georg Groetzbach; Rupert Sandbrink; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2863.

ARVO Annual Meeting Abstract March 2012

Intravitrial Aflibercept Injection for Macular Edema in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 GALILEO Study

Frank G. Holz; Yuichiro Ogura; Johann Roider; Jean-Francois Korobelnik; Brigitte Stemper; Robert Vitti; Alyson J. Berliner; Florian Hiemeyer; Rupert Sandbrink; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6929.

ARVO Annual Meeting Abstract March 2012

Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration

Daniel B. Roth; Jeffrey S. Heier; Desmond Thompson; Yuhwen Soo; Robert Vitti; Namrata Saroj; Alyson J. Berliner; Georg Groeztbach; Olaf Sowade; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2042.

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

A 96-week PULSAR subgroup analysis: Similar visual and anatomic improvements with aflibercept 8 mg every 12 weeks or longer and 2 mg every 8 weeks, as defined by baseline BCVA, CRT, CNV type, and race

From the Human Blood Metabolome to an Interventional Murine CNV Model: Unveiling Saccharin's Protective Effect on Neovascular AMD

Choroidal Vessel Analysis in Central Serous Chorioretinopathy: Real-World Data from the Berlin Macula Registry

Exploring the Impact of Saccharin on Neovascular Age-Related Macular Degeneration: A Comprehensive Study in Patients and Mice

Transcriptome analysis of the human choroid qualifies endothelial androgen responses as a disease driver for Central Serous Chorioretinopathy

Metabolic factors influence CNV activity in neovascular AMD – insights from the BIOMAC study

Phase I/IIa study examining the safety and tolerability of single and multiple rising intravitreal doses of BI 836880 in patients with wAMD

Modulation of clinical neovascular AMD activity by systemic proteome – an analysis from the BIOMAC study

Systemic Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor (VEGF) Agents in Patients With Wet Age-Related Macular Degeneration

A combined phase 2a/b study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops in treatment-naïve patients with neovascular age-related macular degeneration (nAMD)

Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema: Evaluating the Impact on Diabetic Retinopathy

Intravitreal aflibercept shows consistent outcomes in Asian and white patients with wet age-related macular degeneration: novel results from the SIGHT and VIEW studies

Effect of Baseline Central Retinal Thickness (CRT) and Best Corrected Visual Acuity (BCVA) on Treatment Outcomes With Intravitreal Aflibercept Injection (IAI) or Macular Laser Photocoagulation in Diabetic Macular Edema (DME)

Vascular Dysfunction in Ocular Blood Flow Regulation: Impact of Reactive Oxygen Species in an Experimental Setup

Efficacy and Safety of Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Pathological Myopia: 48-week Results of MYRROR Study

Subanalysis of Visual Acuity Outcomes in the Second Year of VIEW Studies

Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Microperimetry assessment of retinal sensitivity in patients with diabetic macular edema - results from the Phase 2 Da Vinci study

Intravitrial Aflibercept Injection for Macular Edema in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 GALILEO Study

Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration

To View More...

You must be signed into an individual account to use this feature.